[Comment] GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis

In The Lancet Diabetes & Endocrinology, Søren Kristensen and colleagues present a new, up-to-date systematic review and meta-analysis1 of cardiovascular outcome trials evaluating glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes—a timely update after the recent reporting of the primary results from the REWIND trial of dulaglutide2,3 and the PIONEER 6 trial of oral semaglutide.4 Incorporating these new trials means that the new meta-analysis includes data from seven trials with a total of 56 004 patients and, of those with available data for the primary outcome of major adverse cardiovascular events (MACE), includes a minority of 12 983 patients who did not have established cardiovascular disease but rather had multiple cardiovascular risk factors (thus being considered primary prevention patients) and 10 773 patients with an estimated glomerular filtration rate of less than 60 mL/min per 1·73 m2.

Bekijk het originele bericht